论文部分内容阅读
新霉胺(neamine)是一种无毒的新霉素(neomycin)降解产物;已有研究证明,其可抑制血管生成素(angiogenin,ANG)诱导的内皮细胞血管生成作用,阻滞异种移植的人结肠腺癌在裸鼠的生长.本研究证明,新霉胺对人黑色瘤细胞株A375的细胞增殖、迁移和侵润作用.MTT法及软琼脂培养显示,新霉胺可明显抑制A375细胞的增殖和集落形成能力.Transwell试验证明,新霉胺可阻滞A375细胞,乃至血管生成素诱导的A375细胞的迁移和侵润能力.此外,免疫荧光揭示新霉胺可阻断血管生成素的核转位,从而抑制血管生成素诱导的A375细胞增殖.上述结果提示,新霉胺可通过抑制血管生成素的核转位,从而抑制肿瘤细胞增殖、迁移和侵润.鉴于与新霉素比较,新霉胺毒性小,因此新霉胺可望作为黑色素瘤治疗的先导药物,颇具开发前景和潜力.
Neamine is a non-toxic degradation product of neomycin. It has been reported that it inhibits angiogenic (ANG) -induced endothelial cell angiogenesis and blocks xenograft Human colon adenocarcinoma growth in nude mice.This study demonstrated that neamine on human melanoma cell line A375 cell proliferation, migration and invasion.MTT method and soft agar culture showed that neamine can significantly inhibit A375 cells Proliferation and colony formation ability.Transwell test proved that neamine can block A375 cells and angiogenin-induced migration and invasion ability of A375 cells.In addition, immunofluorescence revealed that neamine can block the angiogenin Nuclear translocation, thereby inhibiting Angiopoietin-induced A375 cell proliferation.The above results suggest that neamine can inhibit the nuclear translocation of angiogenin, thereby inhibiting tumor cell proliferation, migration and invasion.In view of the comparison with neomycin , Neotetramin toxicity is small, so neaminemycin is expected as a melanoma treatment of lead drugs, considerable development prospects and potential.